Relationship between Sex, Body Size, and Cardiac Resynchronization Therapy Benefit: A Patient Level Meta-Analysis of Randomized Controlled Trials.

QRS cardiac resynchronization therapy heart failure meta-analysis sex

Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
13 Feb 2024
Historique:
received: 07 10 2023
revised: 24 01 2024
accepted: 26 01 2024
medline: 16 2 2024
pubmed: 16 2 2024
entrez: 15 2 2024
Statut: aheadofprint

Résumé

Women might benefit more from cardiac resynchronization therapy(CRT) than men, and do so at shorter QRS durations(QRSd). To determine if sex-based differences in CRT effects are better accounted for by height, body surface area (BSA), or left ventricular end-diastolic dimension(LVEDD). We analyzed patient-level data from CRT trials (MIRACLE, MIRACLE-ICD, MIRACLE-ICD II, REVERSE, RAFT, COMPANION, and MADIT-CRT) using Bayesian Hierarchical Weibull regression models. Relationships between QRSd and CRT effects were examined overall and in sex-stratified cohorts; additional analyses indexed QRSd by height, BSA, or LVEDD. Endpoints were heart failure hospitalization (HFH) or death and all-cause mortality. Compared with men (n=5,628), women (n=1,439) were shorter (1.62[IQR 1.57-1.65]m versus 1.75[IQR 1.70-1.80]m; p<0.001) with smaller BSAs (1.76[IQR 1.62-1.90]m Although body size partially explains sex-specific QRSd thresholds for CRT benefit, it is not associated with the magnitude of CRT benefit. Indexing QRSd for body size might improve patient selection for CRT, particularly with a "borderline" QRSd.

Sections du résumé

BACKGROUND BACKGROUND
Women might benefit more from cardiac resynchronization therapy(CRT) than men, and do so at shorter QRS durations(QRSd).
OBJECTIVE OBJECTIVE
To determine if sex-based differences in CRT effects are better accounted for by height, body surface area (BSA), or left ventricular end-diastolic dimension(LVEDD).
METHODS METHODS
We analyzed patient-level data from CRT trials (MIRACLE, MIRACLE-ICD, MIRACLE-ICD II, REVERSE, RAFT, COMPANION, and MADIT-CRT) using Bayesian Hierarchical Weibull regression models. Relationships between QRSd and CRT effects were examined overall and in sex-stratified cohorts; additional analyses indexed QRSd by height, BSA, or LVEDD. Endpoints were heart failure hospitalization (HFH) or death and all-cause mortality.
RESULTS RESULTS
Compared with men (n=5,628), women (n=1,439) were shorter (1.62[IQR 1.57-1.65]m versus 1.75[IQR 1.70-1.80]m; p<0.001) with smaller BSAs (1.76[IQR 1.62-1.90]m
CONCLUSION CONCLUSIONS
Although body size partially explains sex-specific QRSd thresholds for CRT benefit, it is not associated with the magnitude of CRT benefit. Indexing QRSd for body size might improve patient selection for CRT, particularly with a "borderline" QRSd.

Identifiants

pubmed: 38360252
pii: S1547-5271(24)00128-0
doi: 10.1016/j.hrthm.2024.01.058
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Daniel J Friedman (DJ)

Division of Cardiology, Duke University School of Medicine, Durham, NC; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC. Electronic address: daniel.friedman@duke.edu.

Antonio Olivas-Martinez (A)

Department of Biostatistics, University of Washington, Seattle, WA.

Frederik Dalgaard (F)

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Department of Medicine, Nykøbing Falster Sygehus, Nykøbing, Denmark.

Marat Fudim (M)

Division of Cardiology, Duke University School of Medicine, Durham, NC; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Division of Cardiology, Wroclaw University, Poland.

William T Abraham (WT)

Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH.

John G F Cleland (JGF)

National Heart and Lung Institute, Royal Brompton & Harefield Hospitals, Imperial College, London, UK and British Heart Foundation Centre of Research Excellence. School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow. UK.

Anne B Curtis (AB)

Department of Medicine, University at Buffalo, Buffalo, NY.

Michael R Gold (MR)

Department of Medicine, Medical University of South Carolina, Charleston, SC.

Valentina Kutyifa (V)

Division of Cardiology, Department of Medicine, University of Rochester Medical Center Rochester, NY.

Cecilia Linde (C)

Karolinska Institutet and Department of Cardiology, Karolinska University, Stockholm, Sweden.

Anthony S Tang (AS)

Department of Medicine, Western University, Ontario, Canada.

Fatima Ali-Ahmed (F)

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.

Lurdes Y T Inoue (LYT)

Department of Biostatistics, University of Washington, Seattle, WA.

Gillian D Sanders (GD)

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Duke-Margolis Center for Health Policy, Duke University, Durham, NC; Evidence Synthesis Group, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC.

Sana M Al-Khatib (SM)

Division of Cardiology, Duke University School of Medicine, Durham, NC; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.

Classifications MeSH